Geoffrey I. Shapiro, MD, PhD

Publications

• Lorusso P, Shapiro GI, Hurwitz H, Pilat MJ, Chemidlin J, Kollia G, Syed S, Fischer B, Masson E.Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid
  21461891
• Raina D, Kosugi M, Ahmad R, Panchamoorthy G, Rajabi H, Alam M, Shimamura T, Shapiro GI, Supko JG, Kharbanda S, Kufe DW.DEPENDENCE ON THE MUC1-C ONCOPROTEIN IN NON-SMALL CELL LUNG CANCER CELLS WITH EGFR AND K-RAS MUTATIONS.Mol Cancer Ther. 2011 Mar 18.
  21421804
• Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, Hann CL, McKeegan EM, Litvinovich E, Hemken PM, Dive C, Enschede SH, Nolan C, Chiu YL, Busman T, Xiong H, Krivoshik AP, Humerickhouse R, Shapiro GI, Rudin CM.Phase I study of Navi
  21282543
• Diamond JR, Bastos BR, Hansen RJ, Gustafson DL, Eckhardt SG, Kwak EL, Pandya SS, Fletcher GC, Pitts TM, Kulikowski GN, Morrow M, Arnott J, Bray MR, Sidor C, Messersmith W, Shapiro GI.Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076,
  21131552
• Quek R, Wang Q, Morgan JA, Shapiro GI, Butrynski JE, Ramaiya N, Huftalen T, Jederlinic N, Manola J, Wagner AJ, Demetri GD, George S.Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and
  21177764
• Krug LM, Crawford J, Ettinger DS, Shapiro GI, Spigel D, Reiman T, Temel JS, Michelson GC, Young DY, Hoch U, Adelman DC.Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer.J Thorac O
  21252718
• Shapiro GI, Tibes R, Gordon MS, Wong BY, Eder JP, Borad MJ, Mendelson DS, Vogelzang NJ, Bastos BR, Weiss GJ, Fernandez C, Sutherland W, Sato H, Pierceall WE, Weaver D, Slough S, Wasserman E, Kufe DW, Von Hoff DD, Kawabe T, Sharma S.Phase I Studies of CBP5
  21220472
• Sasaki T, Okuda K, Zheng W, Butrynski J, Capelletti M, Wang L, Gray NS, Wilner K, Christensen JG, Demetri G, Shapiro GI, Rodig SJ, Eck MJ, Jänne PA.The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-trans
  21030459
• Rodig SJ, Shapiro GI.Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.Curr Opin Investig Drugs. 2010 Dec;11(12):1477-90.
  21154129
• Chen Z, Sasaki T, Tan X, Carretero J, Shimamura T, Li D, Xu C, Wang Y, Aldelmant GO, Capelletti M, Lee HJ, Rodig SJ, Borgman CL, Park SI, Kim HR, Padera RF, Marto J, Gray N, Kung AL, Shapiro GI, Janne PA, Wong KK.Inhibition of ALK, PI3K/MEK and HSP90 in M
  20952506
• Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J
  20979469
• Butrynski JE, D'Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC, Ladanyi M, Capelletti M, Rodig SJ, Ramaiya N, Kwak EL, Clark JW, Wilner KD, Christensen JG, Jänne PA, Maki RG, Demetri GD, Shapiro GI.Crizotinib in ALK-rearranged inflammator
  20979472
• Johnson N, Shapiro GI.Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor–chemotherapy combinations as an anticancer strategy for solid tumors.Expert Opin Ther Targets. 2010 Nov;14(11):1199-212.
  20932174
• Eder JP, Shapiro GI, Appleman L, Zhu AX, Miles D, Keer HN, Cancilla B, Chu F, Hitchcock-Bryan S, Sherman L, McCallum SW, Heath EI, Boerner SA, Lorusso P.A Phase I Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics
  20472683
• Wiedemeyer WR, Dunn IF, Quayle SN, Zhang J, Chheda MG, Dunn GP, Zhuang L, Rosenbluh J, Chen S, Xiao Y, Shapiro GI, Hahn WC, Chin L.Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM.Proc Natl Acad Sci U S A. 2010
  20534551
• Carretero J, Shimamura T, Rikova K, Jackson AL, Wilkerson MD, Borgman CL, Buttarazzi MS, Sanofsky BA, McNamara KL, Brandstetter KA, Walton ZE, Gu TL, Silva JC, Crosby K, Shapiro GI, Maira SM, Ji H, Castrillon DH, Kim CF, García-Echeverría C, Bardeesy N,
  20541700
• Tolcher AW, Appleman LJ, Shapiro GI, Mita AC, Cihon F, Mazzu A, Sundaresan PR.A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.Cancer Chemother Pharmacol. 2010 Jun 3.
  20521052
• Cleary JM, Shapiro GI.Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancer.Curr Oncol Rep. 2010 Mar;12(2):87-94. Review.
  20425592
• Fidias P, Pennell NA, Boral AL, Shapiro GI, Skarin AT, Eder JP, Kwoh TJ, Geary RS, Johnson BE, Lynch TJ, Supko JG.Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously u
  19704336
• Johnson N, Cai D, Kennedy RD, Pathania S, Arora M, Li YC, D'Andrea AD, Parvin JD, Shapiro GI.Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage.Mol Cell. 2009 Aug 14;35(3):327-39.
  19683496
• Sos ML,Michel K,Zander T,Weiss J,Frommolt P,Peifer M,Li D,Ullrich R,Koker M,Fischer F,Shimamura T,Rauh D,Mermel C,Fischer S,Stuckrath I,Heynck S,Beroukhim R,Lin W,Winckler W,Shah K,LaFramboise T,Moriarty WF,Hanna M,Tolosi L,Rahnenfuhrer J,Verhaak R,Chiang
  19451690
• Wong KK,Fracasso PM,Bukowski RM,Lynch TJ,Munster PN,Shapiro GI,Janne PA,Eder JP,Naughton MJ,Ellis MJ,Jones SF,Mekhail T,Zacharchuk C,Vermette J,Abbas R,Quinn S,Powell C,Burris HA.A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor
  19318484
• Perera SA,Li D,Shimamura T,Raso MG,Ji H,Chen L,Borgman CL,Zaghlul S,Brandstetter KA,Kubo S,Takahashi M,Chirieac LR,Padera RF,Bronson RT,Shapiro GI,Greulich H,Meyerson M,Guertler U,Chesa PG,Solca F,Wistuba II,Wong KK.HER2YVMA drives rapid development of ad
  19122144
• Ullrich RT,Zander T,Neumaier B,Koker M,Shimamura T,Waerzeggers Y,Borgman CL,Tawadros S,Li H,Sos ML,Backes H,Shapiro GI,Wolf J,Jacobs AH,Thomas RK,Winkeler A.Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thy
  19079597
• Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, Rettig WJ, Meyerson M, Solca F, Greulich H, Wong KK.BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer mo
  18408761
• Shimamura T,Li D,Ji H,Haringsma HJ,Liniker E,Borgman CL,Lowell AM,Minami Y,McNamara K,Perera SA,Zaghlul S,Thomas RK,Greulich H,Kobayashi S,Chirieac LR,Padera RF,Kubo S,Takahashi M,Tenen DG,Meyerson M,Wong KK,Shapiro GI.Hsp90 inhibition suppresses mutant E
  18632637
• Lynch TJ Jr,Blumenschein GR Jr,Engelman JA,Espinoza-Delgado I,Govindan R,Hanke J,Hanna NH,Heymach JV,Hirsch FR,Janne PA,Lilenbaum RC,Natale RB,Riely GJ,Sequist LV,Shapiro GI,Shaw A,Shepherd FA,Socinski M,Sorensen AG,Wakelee HA,Weitzman A.Summary statement
  18520291
• Shimamura T,Shapiro GI.Heat shock protein 90 inhibition in lung cancer.J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S152-9. Review.
  18520302
• Deng J, Shimamura T, Perera S, Carlson NE, Cai D, Shapiro GI, Wong KK, Letai A.Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion.Cancer Res. 2007 Dec 15;67(24):118
  18089817
• Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, Althaus IW, Gandhi L, Shapiro GI, Nelson JM, Heymach JV, Meyerson M, Wong KK, Jänne PA.PF00299804, an irreversible pan-ERBB inhibitor, is
  18089823
• Yuza Y, Glatt KA, Jiang J, Greulich H, Minami Y, Woo MS, Shimamura T, Shapiro G, Lee JC, Ji H, Feng W, Chen TH, Yanagisawa H, Wong KK, Meyerson M.Allele-Dependent Variation in the Relative Cellular Potency of Distinct EGFR Inhibitors.Cancer Biol Ther. 200
  17495523
• Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera SA, Liang MC, Cai D, Naumov GN, Bao L, Contreras CM, Li D, Chen L, Krishnamurthy J, Koivunen J, Chirieac LR, Padera RF, Bronson RT, Lindeman NI, Christiani DC
  17676035
• Minami Y, Shimamura T, Shah K, Laframboise T, Glatt KA, Liniker E, Borgman CL, Haringsma HJ, Feng W, Weir BA, Lowell AM, Lee JC, Wolf J, Shapiro GI, Wong KK, Meyerson M, Thomas RK.The major lung cancer-derived mutants of ERBB2 are oncogenic and are associ
  17311002
• Li D, Shimamura T, Ji H, Chen L, Haringsma HJ, McNamara K, Liang MC, Perera SA, Zaghlul S, Borgman CL, Kubo S, Takahashi M, Sun Y, Chirieac LR, Padera RF, Lindeman NI, Jänne PA, Thomas RK, Meyerson ML, Eck MJ, Engelman JA, Shapiro GI, Wong KK.Bronchial an
  17613438
• Kobayashi S, Shimamura T, Monti S, Steidl U, Hetherington CJ, Lowell AM, Golub T, Meyerson M, Tenen DG, Shapiro GI, Halmos B.Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signal
  17145885
• Cai D, Latham VM, Zhang X, Shapiro GI.Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells.Cancer Res. 2006 Sep 15;66(18):9270-80.
  16982772
• Gizatullin F, Yao Y, Kung V, Harding MW, Loda M, Shapiro GI.The Aurora Kinase Inhibitor VX-680 Induces Endoreduplication and Apoptosis Preferentially in Cells with Compromised p53-Dependent Postmitotic Checkpoint Function.Cancer Res. 2006 Aug 1;66(15):766
  16885368
• Shimamura T, Ji H, Minami Y, Thomas RK, Lowell AM, Shah K, Greulich H, Glatt KA, Meyerson M, Shapiro GI, Wong KK.Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal
  16818618
• Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, Mahmood U, Mitchell A, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Kim W, Jänne PA, Shapiro GI, Tenen D, Johnson BE, Weissleder R, Sharpless NE, Wong KK.The impact of human EGFR kinase d
  16730237
• Ji H, Zhao X, Yuza Y, Shimamura T, Li D, Protopopov A, Jung BL, McNamara K, Xia H, Glatt KA, Thomas RK, Sasaki H, Horner JW, Eck M, Mitchell A, Sun Y, Al-Hashem R, Bronson RT, Rabindran SK, Discafani CM, Maher E, Shapiro GI, Meyerson M, Wong KK.Epidermal
  16672372
• Shapiro GI.Cyclin-dependent kinase pathways as targets for cancer treatment.J Clin Oncol. 2006 Apr 10;24(11):1770-83. Review.
  16603719
• Cai D, Byth KF, Shapiro GI.AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9.Cancer Res. 2006 Jan 1;66(1):435-44.
  16397259
• Shimamura T, Lowell AM, Engelman JA, Shapiro GI.Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins.Cancer Res. 2005 Jul 15;65(14):
  16024644
• Goffin JR, Anderson IC, Supko JG, Eder JP, Shapiro GI, Lynch TJ, Shipp M, Johnson BE, Skarin AT.Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cance
  15867243
• Lechpammer M, Xu X, Ellis FH, Bhattacharaya N, Shapiro GI, Loda M.Flavopiridol reduces malignant transformation of the esophageal mucosa in p27 knockout mice.Oncogene. 2005 Mar 3;24(10):1683-8.
  15674336
• Haddad RI, Weinstein LJ, Wieczorek TJ, Bhattacharya N, Raftopoulos H, Oster MW, Zhang X, Latham VM, Costello R, Faucher J, DeRosa C, Yule M, Miller LP, Loda M, Posner MR, Shapiro GI.A phase II clinical and pharmacodynamic study of E7070 in patients with m
  15269140
• Lynch TJ, Adjei AA, Bunn PA, DuBois RN, Gandara DR, Giaccone G, Govindan R, Herbst RS, Johnson BE, Khuri FR, Perez-Soler R, Rosell R, Rowinsky EK, Sandler AB, Scagliotti GV, Schiller JH, Shapiro GI, Socinski MA, Hart CS.Novel agents in the treatment of lu
  15217958
• Shapiro GI.Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol.Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4270s-4275s.
  15217973
• Zhang GJ, Safran M, Wei W, Sorensen E, Lassota P, Zhelev N, Neuberg DS, Shapiro G, Kaelin WG.Bioluminescent imaging of Cdk2 inhibition in vivo.Nat Med. 2004 Jun;10(6):643-8.
  15122251
• Hofer MD, Kuefer R, Varambally S, Li H, Ma J, Shapiro GI, Gschwend JE, Hautmann RE, Sanda MG, Giehl K, Menke A, Chinnaiyan AM, Rubin MA.The role of metastasis-associated protein 1 in prostate cancer progression.Cancer Res. 2004 Feb 1;64(3):825-9.
  14871807
• Jiang J, Matranga CB, Cai D, Latham VM, Zhang X, Lowell AM, Martelli F, Shapiro GI.Flavopiridol-induced apoptosis during S phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity.Cancer Res. 2003 Nov 1;63(21):7410-22.
  14612540
• Hoang T, Kim K, Jaslowski A, Koch P, Beatty P, McGovern J, Quisumbing M, Shapiro G, Witte R, Schiller JH.Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer.Lung Cancer. 2003 Oct;42(1):97-102.
  14512193
• Matranga CB, Shapiro GI.Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase.Cancer Res. 2002 Mar 15;62(6):1707-17.
  11912144
• Maulik G, Kijima T, Ma PC, Ghosh SK, Lin J, Shapiro GI, Schaefer E, Tibaldi E, Johnson BE, Salgia R.Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.Clin Cancer Res. 2002 Feb;8(2):620-7.
  11839685
• Fidias P, Supko JG, Martins R, Boral A, Carey R, Grossbard M, Shapiro G, Ostler P, Lucca J, Johnson BE, Skarin A, Lynch TJ.A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer.Clin Cancer Res. 2001 Dec;7(12):3
  11751486
• Shapiro GI, Supko JG, Patterson A, Lynch C, Lucca J, Zacarola PF, Muzikansky A, Wright JJ, Lynch TJ, Rollins BJ.A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cance
  11410495
• Shapiro GI, Koestner DA, Matranga CB, Rollins BJ.Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines.Clin Cancer Res. 1999 Oct;5(10):2925-38.
  10537362
• Salgia R, Li JL, Ewaniuk DS, Wang YB, Sattler M, Chen WC, Richards W, Pisick E, Shapiro GI, Rollins BJ, Chen LB, Griffin JD, Sugarbaker DJ.Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility.Oncogene. 1999 Ja
  9926921
• Shapiro GI, Edwards CD, Ewen ME, Rollins BJ.p16INK4A participates in a G1 arrest checkpoint in response to DNA damage.Mol Cell Biol. 1998 Jan;18(1):378-87.
  9418885
• Shapiro GI, Park JE, Edwards CD, Mao L, Merlo A, Sidransky D, Ewen ME, Rollins BJ.Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines.Cancer Res. 1995 Dec 15;55(24):6200-9.
  8521414